 Obesity is a major contributor to chronic kidney disease, CKD, as well as type 2 diabetes. Randomized control trials have shown that sodium glucose-cotransporter 2 inhibitors, glucagon-like peptid 1 analogues, and bariatric surgery can improve renal outcomes in patients with both conditions. Further research is needed to better understand how these treatments can be used to reduce morbidity in patients with obesity and CKD. This article was authored by Roshida Abdul Wahab, Ricardo V. Cohen and Carol W. LaRue.